SANTA BARBARA, Calif., April 29, 2021 /PRNewswire/ — Bexson Biomedical, Inc., a research-stage company developing therapies and delivery solutions for pain management, addiction and mental health indications, announced today that the U.S. Patent and Trademark Office (USPTO) has granted Bexson U.S. Pat. No. 10,973,780, describing pharmaceutical formulations and treatment methods including the…


Previous articleLobe Sciences Announces Filing of PCT Application
Next articleOp-Ed: Re-evaluating the Results of the Recent Trial of Psilocybin vs Escitalopram for Depression